myeloma

The International Myeloma Foundation Invites the Myeloma Community to Demonstrate the Spirit of #MoreThanMyeloma for 2026 Myeloma Action Month

STUDIO CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Every March, the International Myeloma Foundation (IMF) leads Myeloma Action Month…

4 months ago

Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial…

7 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

September 20, 2025 11:00 ET  | Source: C4 Therapeutics, Inc. Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response…

10 months ago

Multiple Myeloma Research Foundation (MMRF) Announces New Data from Flagship Research Initiatives at the 22nd International Myeloma Society Annual Meeting

NORWALK, Conn., Sept. 20, 2025 (GLOBE NEWSWIRE) -- Today, the Multiple Myeloma Research Foundation® (MMRF) announced that data generated from…

10 months ago

Press Release: Sanofis Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase…

11 months ago

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

1 year ago